© 2017 Evestra, Inc.


Evestra’s management team is building an innovative international biopharmaceutical business by pursuing the following strategy:

· Establish an attractive portfolio of near-term and innovative women's healthcare products that enables Evestra to be the next leader in women’s healthcare product innovation in the US

· Get first market access for product(s) through co-marketing agreements with established players

· Develop new market product leaders in each market segment by targeting high medical need areas, such as reduced rates of deep vein thrombosis in contraception

· Address market needs for long-term products through drug delivery approaches such as vaginal rings and injectable products

· Develop products in a cost-effective matter through global reach

· Finance innovative R&D activities by

· Licensing out development and  marketing rights for innovative women’s health projects for  Europe and Latin America

· Generating income from partnerships around generic vaginal ring products

· Drug development grants from European Union through Polish subsidiary

· Drug development grants from other foundations focused on women’s health issues

· Placements of equity

· Opportunistically utilize internal R&D capabilities to generate innovative non-core assets in oncology and andrology and sell them to finance core activities

Evestra’s development products could be categorized in three product classes with clear strategic intent: